<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00973037</url>
  </required_header>
  <id_info>
    <org_study_id>AN09020</org_study_id>
    <nct_id>NCT00973037</nct_id>
  </id_info>
  <brief_title>CYP2D6 Genotype on the Clinical Effect of Tamoxifen</brief_title>
  <acronym>ASTRRA-CYP2D6</acronym>
  <official_title>Impact of CYP2D6 Genotype on the Clinical Effects of Tamoxifen Using With Samples From Prospective Randomized Multicenter Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea University Anam Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Center, Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Korean Breast Cancer Study Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Korea University Anam Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the impact of CYP2D6 Genotype on the clinical
      effects of tamoxifen using with samples from prospective randomized multicenter
      study(ASTRRA).
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2009</start_date>
  <completion_date type="Anticipated">April 2016</completion_date>
  <primary_completion_date type="Anticipated">April 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival(DFS)</measure>
    <time_frame>5years</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">922</enrollment>
  <condition>Breast Neoplasms</condition>
  <condition>Tamoxifen</condition>
  <condition>Genotype</condition>
  <condition>CYP2D6</condition>
  <arm_group>
    <arm_group_label>CYP2D6</arm_group_label>
    <description>CYP2D6 genotype</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamoxifen</intervention_name>
    <description>Tamoxifen 20mg qd</description>
    <arm_group_label>CYP2D6</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        young women(â‰¤45 years) with hormone-sensitive breast cancer who remain in premenopause or
        regain menstruation after chemotherapy
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient must sign the informed consent form.

          -  The patient must sign the informed consent of genotype screening test.

          -  The patient must be between 18 years old and 45 years old who can make a decision
             independently.

          -  Patients must have undergone excision of the primary breast mass, proven
             histologically to be invasive breast adenocarcinoma.(The type of mastectomy performed,
             number of axillary nodes removed, number of axillary nodes found positive, and tumor
             size must be included on the CRFs. For patients who have more than one discrete tumor
             masses should be measured and reported on the CRFs.)

          -  Patients must be within 3 months after the last cycle of chemotherapy.

          -  Patients must have the history of normal menstruation prior to the start of
             chemotherapy.

          -  Stage I, II or III

          -  Woman, less than or equal to 45 years of age

          -  The test result of the estrogen receptor is positive.

          -  WHO performance status 0, 1 or 2.

          -  Patients who were treated with cytotoxic chemotherapy in pre or post surgery.
             Permissible prior chemotherapy; currently locally available and approved standard
             chemotherapy in the adjuvant or neoadjuvant setting: e.g.,
             AC(Doxorubicin/cyclophosphamide) followed by taxane, AC(Doxorubicin/cyclophosphamide),
             TA(Docetaxel/ Doxorubicin), FAC(5-fluorouracil/ doxorubicin / cyclophosphamide) or
             others.

          -  Adequate hematological function defined by hemoglobin 10g/dl, neutrophil count 1.5 X
             10 9/L and platelets 100 X 10 9/L.

          -  Adequate hepatic function defined by AST and ALT 2.5 X upper limit of normal. Alkaline
             phosphatase 5 X upper limit of normal, unless bone metastases in the absence of liver
             disease. Renal function adequate defined by creatinine &lt; 175 mmol/L.

        Exclusion Criteria:

          -  The test result of the estrogen receptor is negative or unknown.

          -  Patients with the history of hysterectomy or oophorectomy.

          -  Sarcomas or squamous cell carcinomas of the breast are not eligible.

          -  Patients with malignancies(other than breast cancer) within the last 5 years, except
             for adequately treated in situ carcinoma of the cervix or basal cell/squamous cell
             carcinoma of the skin.

          -  Investigational drugs given within the previous 4 weeks.

          -  Patients with thrombocytopenia (platelets &lt; 100 X 10 9/L or on anti-coagulant
             therapy(contra-indicated due to risk of bleeding with i.m. injection of Zoladex).

          -  Patients treated with CMF(cyclophosphamide/methotrexate/5-fluorouracil) as prior
             chemotherapy.

          -  Patients who are pregnant or lactating are ineligible.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eun Sook Lee, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University Anam Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eun Sook Lee, MD, PhD</last_name>
    <phone>82-2-920-6744</phone>
    <email>eslee@korea.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Korea University Anam Hopital</name>
      <address>
        <city>Seoul</city>
        <zip>136-705</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eun Sook Lee, MD, PhD</last_name>
      <phone>82-2-920-6744</phone>
      <email>eslee@korea.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Eun Sook Lee, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2009</study_first_submitted>
  <study_first_submitted_qc>September 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2009</study_first_posted>
  <last_update_submitted>September 8, 2009</last_update_submitted>
  <last_update_submitted_qc>September 8, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2009</last_update_posted>
  <responsible_party>
    <name_title>Eun Sook, Lee</name_title>
    <organization>Korea University Anam Hospital</organization>
  </responsible_party>
  <keyword>Breast neoplasms</keyword>
  <keyword>Tamoxifen</keyword>
  <keyword>Genotype</keyword>
  <keyword>CYP2D6</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

